🟢 Telix Pharmaceuticals is trading 4.77% up in pre-market after announcing US$1.65 billion ITM acquisition

Telix Pharmaceuticals is trading 4.77% up at $11.85 after announcing its US$1.65 billion acquisition of ITM Isotope Technologies Munich.

• The transaction includes approximately US$1.25 billion in Telix shares, creating dilution; potential contingent payments could reach US$700 million.
• Telix Pharmaceuticals fell 10.17% to $11.31 on September 21; the pre-market move indicates a partial recovery from the acquisition-driven selloff.